Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wang, Danhong ^a   Zhang, Bin ^a   Gao, Haiyan ^a   Ding, Guoliang ^a   Wu, Qiong ^a   Zhang, Jinchao ^a   Liao, Li ^a   Chen, Hu ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Advanced renal cancer; Clinical research; Cytokine Induced Killer cell; Dendritic cells

Indexed keywords

CANCER VACCINE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE INDUCED KILLER CELL VACCINE; DENDRITIC CELL VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MALE; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADVERSE DRUG REACTION; BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; IMMUNOLOGY; KIDNEY NEOPLASMS; PATHOLOGY;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE;

EID: 84899484996     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-251     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ. Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res 2011, 1:240-254. 3180049, 21969126.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
4. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012, 8:35-40.
5. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478. 10.1016/j.immuni.2010.10.007, 2975953, 21029958.
6. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999, 81:1009-1016. 10.1038/sj.bjc.6690800, 2362953, 10576658.
7. Thanendrarajan S1, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res 2011, 35:1136-1142. 10.1016/j.leukres.2011.05.005, 21652069.
8. Sun Y, Chen J, Cai P, Hu YH, Zhong GC, Feng HZ. Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendric cells-activated lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:219-223.
9. Yagoda A, Bander NH. Failure of cytotoxic chemotherapy,1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989, 44:338-345. 10.1159/000281537, 2696193.
10. Hirschowitz E, Foody T, Hidalgo G, Yannelli J. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372. 10.1016/j.lungcan.2007.04.002, 2063443, 17509725.
11. Yang B, Lu XC, Zhu HL, Han WD, Wang Y, Fan H, Li SX, Liu Y, Dai HR, Yao SQ. Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:1244-1249.
12. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with ALdesleukin (Interleukin2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009, 15:4986-4992. 10.1158/1078-0432.CCR-08-3240, 3775650, 19622576.
13. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 8:1928-1935.
14. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mappingthe way. Nat Med 2004, 10:475-480. 10.1038/nm1039, 15122249.
15. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M,. Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004, 22:1188-1194. 10.1200/JCO.2004.06.155, 14981107, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
16. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunothérapie. N Engl J Med 1998, 338:1272-1278. 10.1056/NEJM199804303381805, 9562581.
17. Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ. Activity of single-agent Bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2013, 11:45-50. 10.1016/j.clgc.2012.06.001, 23041453.
18. Bukowski RM, Eisen T, Szczylik C. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007, 25:abstract5023.
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318. 10.1200/JCO.2008.19.5511, 19451442.
20. Maroto JP, Del Muro XG, Mellado B, Perez-Gracia JL, Andrés R, Cruz J, Gallardo E, Domenech M, Arranz JA, Meana JA. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol 2013, [Epub ahead of print].
21. Lesterhuis WJ1, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nat Rev Drug Discov 2011, 10:591-600. 10.1038/nrd3500, 21804596.
22. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother Nat Rev Drug Discov 2011, 10:591-600.
23. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 18:1388-1397.
24. Knutson KL1, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728. 10.1007/s00262-004-0653-2, 16010587.
25. Kraemer M, Hauser S, Schmidt-Wolf IG. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res 2010, 30:2081-2086.